Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.

Inventors: Daniel W. Norbeck, Dale J. Kempf, John M. Leonard, Richard J. Bertz
Original Assignee: Abbott Laboratories
Primary Examiner: Charanjit S. Aulakh
Current U.S. Classification: 435/184; 514/365; 548/204; 548/205
International Classification: C12N 999; C07D27728

View patent at USPTO
Search USPTO Assignment Database

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US5547823Nov 9, 1995Aug 20, 1996Ishihara Sangyo Kaisha, Ltd.
Akira Fujishima
Kazuhito Hashimoto		Photocatalyst composite and process for producing the same
US5552558Mar 27, 1995Sep 3, 1996Abbott LaboratoriesRetroviral protease inhibiting compounds
US5674882Mar 29, 1995Oct 7, 1997Abbott LaboratoriesRetroviral protease inhibiting compounds
US5886036Mar 20, 1997Mar 23, 1999Abbott LaboratoriesRetroviral protease inhibiting compounds

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US6284767Dec 8, 1998Sep 4, 2001Abbott LaboratoriesRetroviral protease inhibiting compounds
US6472529Apr 18, 2001Oct 29, 2002Abbott LaboratoriesRetroviral protease inhibiting compounds
US6703403Sep 20, 2001Mar 9, 2004Abbott LaboratoriesMethod for improving pharmacokinetics
US7205413May 1, 2003Apr 17, 2007TransForm Pharmaceuticals, Inc.Solvates and polymorphs of ritonavir and methods of making and using the same
US7208600Oct 12, 2004Apr 24, 2007Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A proteases
US7279582Oct 25, 2002Oct 9, 2007Abbott LaboratoriesRetroviral protease inhibiting compounds
US7320961Mar 18, 2004Jan 22, 2008Abbott LaboratoriesMethod for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
US7364752Nov 10, 2000Apr 29, 2008Abbott LaboratoriesSolid dispersion pharamaceutical formulations
US7378422Sep 7, 2004May 27, 2008Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7494660Oct 27, 2004Feb 24, 2009Vertex Pharmaceuticals IncorporatedHCV NS3-NS4A protease resistance mutants
US7547678Jan 15, 2008Jun 16, 2009Abbott LaboratoriesMethod for treating a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate
US7666834Jul 28, 2006Feb 23, 2010Tibotec Pharmaceuticals Ltd.Macrocyclic inhibitors of hepatitis C virus
US7705138Nov 13, 2006Apr 27, 2010Vertex Pharmaceuticals IncorporatedHepatitis C virus variants
US7745444Apr 10, 2008Jun 29, 2010Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7820671Aug 31, 2001Oct 26, 2010Vertex Pharmaceuticals IncorporatedPeptidomimetic protease inhibitors
US7820681Feb 17, 2009Oct 26, 2010Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and a second active agent
US7884199Nov 17, 2008Feb 8, 2011Vertex Pharmaceuticals IncorporatedHCV NS3-NS4 protease resistance mutants
US7906519Aug 18, 2010Mar 15, 2011AR Holding Company, Inc.Methods for concomitant administration of colchicine and a second active agent
US7915269Aug 18, 2010Mar 29, 2011AR Holding Company, Inc.Methods for concomitant administration of colchicine and a second active agent
US7935731May 25, 2010May 3, 2011Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and macrolide antibiotics
US7964624Feb 27, 2007Jun 21, 2011Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US7964648Jan 15, 2010Jun 21, 2011Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and a second active agent
US7968707Feb 27, 2007Jun 28, 2011Abbott LaboratoriesRetroviral protease inhibiting compounds
US7985762Aug 28, 2006Jul 26, 2011Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US7989471Jul 28, 2006Aug 2, 2011Tibotec Pharmaceuticals Ltd.Macrocyclic inhibitors of hepatitis C virus
US8008251Jul 28, 2006Aug 30, 2011Tibotec Pharmaceuticals Ltd.
Medivir AB		Macrocyclic inhibitors of hepatitis C virus
US8012939Jul 28, 2006Sep 6, 2011Tibotec Pharmaceuticals Ltd. Co
Medivir AB		Macrocyclic inhibitors of hepatitis C virus
US8025899Aug 25, 2004Sep 27, 2011Abbott LaboratoriesSolid pharmaceutical dosage form
US8030307Nov 26, 2008Oct 4, 2011Enanta Pharmaceuticals, Inc.Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease
US8039475Feb 27, 2007Oct 18, 2011Vertex Pharmaceuticals IncorporatedCo-crystals and pharmaceutical compositions comprising the same
US8039623Mar 9, 2007Oct 18, 2011Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8073632Dec 30, 2008Dec 6, 2011The Invention Science Fund I, LLCComputational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073633Dec 30, 2008Dec 6, 2011The Invention Science Fund I, LLCComputational methods and systems for suggesting modulators of CYP450 as treatment options
US8093296Apr 20, 2011Jan 10, 2012Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and macrolide antibiotics
US8093297Apr 22, 2011Jan 10, 2012Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and a second active agent
US8093298May 18, 2011Jan 10, 2012Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and macrolide antibiotics
US8097655May 17, 2011Jan 17, 2012Mutual Pharmaceutical Company, Inc.Methods for concomitant administration of colchicine and macrolide antibiotics
US8183277Jul 28, 2006May 22, 2012Tibotec Pharmaceuticals Ltd.Macrocylic inhibitors of hepatitis C virus
US8217048Jun 28, 2010Jul 10, 2012Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8227407Jan 16, 2008Jul 24, 2012Medivir AB
Tibotec BVBA		Macrocyclic inhibitors of hepatitis C virus
USRE42889Apr 23, 2007Nov 1, 2011G.D. Searle LLCα- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors

Claims

1. A method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

3. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

4. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

5. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.

6. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.

7. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.

8. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.

9. A method for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

11. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.

12. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.

13. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.

14. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.

15. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.

16. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.

17. A method for inhibiting cytochrome P450 monooxygenase comprising administering to a human in need thereof an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase.

18. A method for inhibiting cytochrome P450 monooxygenase comprising contacting the cytochrome P450 monooxygenase with an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase.